was digested with Eco RI and Xba I. This fragment was subcloned into the pCaSpeR-hs vector [C. S. Thummel and V. Pirrotta, Drosophila Inf. Serv. 71, 150 (1992)] to generate the hsp70-AS-Pgc transgene. This plasmid was introduced into the germ line of Drosophila with P element-mediated transformation [A. C. Spradling and G. M. Rubin, Science 218, 341 (1982)]. Because pCaSpeR-hs contains the mini-white (w ϩ ) gene, transformed wflies show orange to red eye color.
The fundamental event in prion diseases seems to be a conformational change in cellular prion protein (PrP C ) whereby it is converted into the pathologic isoform PrP Sc . In fatal familial insomnia (FFI), the protease-resistant fragment of PrP Sc after deglycosylation has a size of 19 kilodaltons, whereas that from other inherited and sporadic prion diseases is 21 kilodaltons. Extracts from the brains of FFI patients transmitted disease to transgenic mice expressing a chimeric human-mouse PrP gene about 200 days after inoculation and induced formation of the 19-kilodalton PrP Sc fragment, whereas extracts from the brains of familial and sporadic Creutzfeldt-Jakob disease patients produced the 21-kilodalton PrP Sc fragment in these mice. The results presented indicate that the conformation of PrP Sc functions as a template in directing the formation of nascent PrP Sc and suggest a mechanism to explain strains of prions where diversity is encrypted in the conformation of PrP Sc .
For many years the prion diseases, also called transmissible spongiform encephalopathies, were thought to be caused by slowacting viruses (1), but it is now clear that prions are not viruses and that they are devoid of nucleic acid (2, 3) . Prions seem to be composed only of PrP Sc molecules, which are abnormal conformers of a normal, hostencoded protein designated PrP C (3, 4). PrP C has a high ␣-helical content and is virtually devoid of ␤-sheets, whereas PrP Sc has a high ␤-sheet content (4, 5) ; thus, the conversion of PrP C into PrP Sc involves a profound conformational change. Formation of PrP Sc is a posttranslational process that does not appear to involve a covalent modification of the protein (6) .
The prion diseases are unique in that they may present as inherited and infectious disorders (3, 7). More than 20 different mutations of the human (Hu) PrP gene segregate with dominantly inherited disease; five of these have been genetically linked to familial Creutzfeldt-Jakob disease (fCJD), Gerstmann-Sträussler-Scheinker disease, and fatal familial insomnia (FFI) (8) . The most common prion diseases of animals are scrapie of sheep and bovine spongiform encephalopathy; the latter may have been transmitted to people through foods (9) .
To extend studies on the transmission of wild-type and mutant prions from sporadic Creutzfeldt-Jakob disease (sCJD) and fCJD patients, respectively, to transgenic mice expressing a chimeric mouse-human PrP gene [Tg(MHu2M) mice] (10, 11), we inoculated these mice with mutant prions from the brains of patients who died of FFI. Transmission of human prions to Tg(MHu2M) mice involves the conversion of chimeric MHu2M PrP C into MHu2M PrP Sc through a process that is thought to involve the binding of PrP Sc to PrP C as PrP C undergoes a structural transition (12, 13) . A point mutation of the PrP gene at codon 178 [in which an Asp residue at position 178 is mutated to Asn (D178N)] is the cause of FFI, but a Met residue must be encoded at position 129 on the mutant allele for the FFI phenotype to be manifest (14) . The same D178N mutation segregates with a subtype of fCJD, but in this case, Val is encoded on the mutant allele at position 129. The D178N mutation is thought to destabilize the structure of PrP C , resulting in its transformation into PrP Sc (13, 15) . Some investigators have reported transmission of FFI prions to non-Tg and Tg(HuPrP) mice; the incubation times exceeded 400 days, and only a minority of the inoculated Tg(HuPrP) mice expressing both human and mouse PrP C developed disease (16 The failure to transmit disease with brain homogenates of frontal and insula cortices from FFI patient V-58 is apparently not related to heterozygosity at codon 129, because homogenate from patient IV-16, who has the same haplotype, transmitted the disease. Patients V-58 and IV-16 are phenotypically similar and exemplify the FFI phenotype of the codon 129 heterozygotes with especially long duration (18) . The sleep disorder was comparable in patients V-58 and IV-16, and spongiosis was actually more severe in patient IV-16 than in patient V-58 (18) . It is noteworthy that a homogenate prepared from the parietal cortex of a patient with fCJD(D178N, V/V129) has so far failed to transmit disease. Whether the titer of prions in this particular sample is low or the Val (V) residue at position 129 in combination with the D178N mutation prevents transmission to Tg(MHu2M)Prnp 0/0 mice remains to be established.
Prion proteins in extracts from the brains of Tg(MHu2M) mice inoculated with FFI(D178N, M129) were compared with those inoculated with fCJD(E200K) or sCJD. Mouse brain homogenates were digested with proteinase K (100 g/ml) for 1 hour at 37°C followed by denaturation by boiling in 3% SDS. The denatured PrP Sc was then digested with glycopeptide Nglycosidase (PNGase F) to remove Asnlinked oligosaccharides. As previously described, the human brain extracts prepared from FFI patients yielded a 19-kD protein, whereas extracts from brains of patients with fCJD(E200K) or typical sCJD contained a 21-kD protein (19) . Because the amino acid sequences of HuPrP Sc molecules from FFI and fCJD(E200K) patients differ at two residues, it was not surprising that the conformations of PrP Sc as reflected by the size of the protease-resistant PrP fragments are different (Fig. 1A) . In contrast, it was unexpected that PrP Sc found in Tg(MHu2M) mice inoculated with FFI prions would be 19 kD, whereas that in Tg(MHu2M) mice injected with fCJD(E200K) was 21 kD (Fig. 1A) (Fig. 1B) . We emphasize that whereas the primary structures of the PrP Sc molecules in the three different human brain inocula are distinct, the amino acid sequences of the PrP Sc molecules in the brains of inoculated Tg(MHu2M) mice are invariant. The MHu2M PrP transgene was sequenced and found to be the same as the construct used for microinjections during production of the mice (20) .
We also examined the regional distribution of PrP Sc in the brains of Tg(MHu2M)Prnp 0/0 mice inoculated with prions from FFI patients as well as from fCJD(E200K) and sCJD patients (21) . Histoblots of coronal brain sections through the hippocampus and thalamus as well as those through the brainstem and cerebellum were developed (Fig. 2) In FFI-inoculated mice, PrP Sc deposition was most intense in the thalamus and the rostral part of the corpus callosum ( Fig.  2A) . In FFI patients PrP Sc deposition and neuropathologic changes are marked in the antero-ventral and mediodorsal nuclei of the thalamus (18, 22) . Intermediate intensities of immunostaining were found in the deeper layers of the frontal cortex and in the lateral portions of the caudate nuclei. Little or no immunostaining was found in the habenula or the hypothalamus ( 2A). Staining in the hippocampus was also negative except for the stratum lacunosum molecularae where most of the spongiform degeneration and reactive astrocytic gliosis occurred. The absence of PrP Sc deposition in the habenula is unique to FFI because deposition invariably occurs in this region in response to CJD and scrapie prion inoculations (10, 23) .
In contrast to FFI-inoculated mice, inoculation of Tg(MHu2M) mice with fCJD(E200K) and sCJD prions induced PrP Sc accumulation in many areas of the central nervous system (Fig. 2, B and C) . Although inoculation with fCJD(E200K) and sCJD as well as with iatrogenic CJD prions (24) resulted in accumulations of PrP Sc in the brainstem (Fig. 2, F and G) , that was not the case for FFI (Fig. 2E ). These differences in PrP Sc deposition reflect earlier studies on prion strains where the patterns of spongiform degeneration and PrP Sc accumulation were specific for a particular strain when assessed in isogenic animals (23, 25) .
The neuropathologic changes in the brains of five Tg(MHu2M)Prnp 0/0 mice inoculated with prions from three different FFI patients were examined (Fig. 3 ). They were characterized by moderate to severe spongiform degeneration and astrocytic gliosis in the deeper layers of the frontal cortex and rostral part of the cingulate gyrus, the thalamus, the lateral portions of the caudate nucleus, and in the white matter tracts of the cerebral hemispheres. Immunohistochemical examination of FFI-inoculated brains (Fig. 3B) showed that regions with the largest amount of PrP staining corresponded to the regions with the most severe neuropathological changes in both gray and white matter. The accentuated immunostaining resulted from multiple primitive PrP plaques ranging in size from 10 to 40 M (Fig. 3B) .
Comparison of FFI-inoculated Tg-(MHu2M)Prnp 0/0 mice with the same type mice inoculated with prions from fCJD-(E200K) and sCJD patients revealed two main histopathologic differences. First, FFI produced no vacuolation in the hypothalamus, whereas a mild to moderate degree of vacuolation was found with both sCJD and fCJD(E200K) prions. Secondly, FFI produced moderate to severe vacuolation of the corpus callosum. In contrast, there was only mild vacuolation of the corpus callosum with sCJD and none with fCJD(E200K).
Our studies show that human prions inoculated into Tg(MHu2M)Prnp (21) . PrP C was eliminated from the section by exposing the membranes for 18 hours at 37°C to proteinase K (400 g/ml) in a buffer containing 0.5% Brij 35, 100 mM NaCl, and 10 mM tris-HCl, pH 7.8.
Immunostaining of PrP
Sc was enhanced by exposing the histoblots to 3 M guanidinium isothiocyanate for 10 min at room temperature in 20 mM tris-HCl, pH 7.8, then rinsing three times with TBST [10 mM tris-HCl, pH 8.0, 150 mM NaCl, 0.5% (v/v) Tween 20] before immunostaining with monoclonal antibody 3F4 to PrP (anti-PrP) (31) . Also shown are labeled diagrams of the coronal sections of the hippocampus-thalamus region (D) and brainstem-cerebellum region (H). NC, neocortex; Hp, hippocampus; Hb, habenula; Th, thalamus; vpl, ventral posterior lateral thalamic nucleus; Hy, hypothalamus; Am, amygdala; GC, granular cell layer of the cerebellum; IC, inferior colliculus; R, dorsal nucleus of the raphe; LC, locus ceruleus. mice remains to be determined.
If such properties are propagated, then this will suggest that different mutant human PrPs will have generated distinct strains of prions. The existence of prion strains has posed a conundrum as to the mechanism by which strain-specific characteristics are encrypted (23, 26) . Although differences in the size of protease-resistant fragments of PrP Sc have not been a general characteristic of prion strains (27) , the hyper and drowsy strains of prions isolated from mink by serial passage in Syrian hamsters do differ with respect to the size of the PrP Sc molecules after limited proteolysis (28) . But unlike the studies reported here, where prions were generated de novo in patients carrying the D178N or E200K mutations, the origin of the hyper and drowsy strains is obscure.
Our results provide a plausible mechanism for explaining diversity in a pathogen that lacks nucleic acid; the biological properties of prion strains seem to be encrypted in the conformation of PrP Sc . Because prion strains produce different disease phenotypes, such findings raise the possibility that deviations in the phenotypes of other degenerative disorders may also reflect conformational variants in pathologic proteins. Variations in the conformation of PrP Sc are reproduced through templating of the PrP Sc in the inoculum onto the substrate PrP C . Deciphering the molecular events by which the conformation of one protein is imparted to another and the mechanism responsible for the apparently high degree of fidelity associated with this process should be of considerable interest. Indeed, the foregoing data violate the widely and longheld idea that amino acid sequences are the sole determinants of the tertiary structures of biologically active proteins (29) .
